Knowledge and practice regarding eosinophilic gastrointestinal disorders other than eosinophilic esophagitis among pediatric gastroenterologists of the Latin American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Authors: Sofia Paz, Michelle Higuera Carrillo, Alonso Rafael Echavez Agudelo, Mário Cesar Vieira, Juan Pablo Riveros López, Natali González Rozó, Gustavo Javier Tagliaferro, Fabiola Sánchez Hernández, Catalina Ortiz Piedrahita, Wilson Daza Carreño, Ailim Margarita Carias Domínguez, José Fernando Vera Chamorro, Sabine Krüger Truppel, Maximiliano Fernández Rivas, César Augusto Moreno Serrano, Pablo Torres Córdova, Carlos Marcelo Timossi, Pablo Vásquez Published: 2026 ABSTRACT AbstractObjectiveEvaluating clinical practices in the management of non‐esophageal eosinophilic gastrointestinal disorders (non‐EoE EGIDs) among pediatric gastroenterologists in Latin America.MethodsA cross‐sectional descriptive study was conducted using a survey distributed via the REDCap platform. A total of 309 pediatric gastroenterologists and trainees from 17 Latin American countries (excluding Nicaragua and Bolivia) participated in the study. Data collection took place between March and May 2024.ResultsSixty‐five percent of respondents reported seeing fewer than five cases per year. Only 17.8% consistently collaborate with allergists. While 92.2% perform biopsies in all segments during endoscopy, just 80.9% send specimens in separate containers. Systematic endoscopic monitoring is carried out by 48.9% of practitioners. Ancillary tests such as fecal calprotectin (10.0%) and peripheral eosinophilia (19.4%) are infrequently used. The most common treatment strategies were proton pump inhibitors (44.4%) and elimination diets (40.1%), with systemic corticosteroids (17.4%), viscous budesonide (16.4%), and biologics (11.1%) being less frequently employed.ConclusionsThere is considerable variability in clinical practice regarding non‐EoE EGIDs across Latin America. These findings underscore the urgent need for consensus‐based diagnostic and therapeutic guidelines and highlight the importance of ongoing medical education to improve patient care in this emerging field of pediatric gastroenterology. INTRODUCTION Eosinophilic gastrointestinal disorders (EGIDs) are a group of chronic, complex diseases characterized by abnormal eosinophilic infiltration in different segments of the gastrointestinal tract, in the absence of secondary causes such as infections or autoimmune conditions. 1 , 2 Within this group, eosinophilic esophagitis (EoE) is the most extensively studied and best understood entity. 3 , 4 However, EGIDs affecting other parts of the gastrointestinal tract, commonly referred to as non‐esophageal EGIDs (non‐EoE EGIDs), pose significant challenges in both diagnosis and management due to their lower recognition and the scarcity of specific studies. 3 , 5 Despite the increasing global incidence of EGIDs, their true prevalence in the pediatric population across Latin America remains unknown. The lack of high‐quality studies in the region has generated clinical uncertainty, hindering the identification and treatment of pediatric patients with these conditions. While the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) published a consensus statement in January 2024 providing guidance on the diagnosis and treatment of non‐EoE EGIDs, the absence of local data continues to represent a major limitation, as epidemiological and clinical features may differ between regions. 1 Clinical variability in the diagnostic and therapeutic approaches to EGIDs has been widely documented worldwide. Nonetheless, in Latin America, the extent of such differences remains unclear. In this context, understanding the strategies employed by pediatric gastroenterologists across the region is essential to identify gaps, benchmark practices against international recommendations, and support the development of clinical practice guidelines tailored to local needs. METHODS Ethics statement The questionnaire was pre‐validated by a panel of 10 pediatric gastroenterologists and developed based on the 2024 consensus guidelines of the European and North American Societies for Pediatric Gastroenterology, Hepatology, and Nutrition. Ethical approval was obtained from the Institutional Review Board of Erasmo Meoz University Hospital (Cúcuta, Colombia). Given the anonymous and voluntary nature of the survey, the requirement for informed consent was waived by the Institutional Review Board. Study design and participants A cross‐sectional descriptive study was conducted to evaluate clinical practices in the management of EGIDs other than EoE among pediatric gastroenterologists in Latin America. The survey targeted members of the Latin American Society for Pediatric Gastroenterology, Hepatology and Nutrition (LASPGHAN), the largest pediatric gastroenterology society in the region, comprising 658 active members. Of 407 invited professionals, 309 completed the survey, yielding a response rate of 76.5%. Participants who did not complete the survey were excluded from the analysis. Data were obtained through an online survey developed using the REDCap platform. The questionnaire consisted of 25 multiple‐choice items divided into three sections. The first section collected demographic data, including country of practice, professional environment, and years of clinical experience. The second section addressed diagnostic practices, evaluating the investigations employed for the identification of EGIDs other than EoE. The third section examined therapeutic management, encompassing both pharmacological and non‐pharmacological interventions, as well as treatment duration. Additional details regarding the survey instrument are provided in the File S1. The survey was distributed electronically via e‐mail, social media platforms (WhatsApp, Instagram, and Telegram), and professional discussion groups. Data were collected from April through June 2025 and stored securely in REDCap, ensuring respondent confidentiality and anonymity. Statistical analysis Data analysis was performed using STATA software. Categorical variables were summarized as frequencies and percentages, whereas continuous variables were described using medians and interquartile ranges. Associations between variables were assessed using the chi‐square test or Fisher's exact test for categorical variables and the Student's t‐test or Mann–Whitney U test for continuous variables, as appropriate according to data distribution. A two‐sided p‐value < 0.05 was considered statistically significant. RESULTS A total of 309 completed surveys were analyzed. Of these, 90.6% of respondents were pediatric gastroenterologists, and 9.4% were pediatric gastroenterology trainees. Seventeen countries were represented, with the highest participation from Argentina (29.4%), Colombia (21.7%), Mexico (14.9%), and Brazil (12.0%). The complete distribution of the participants' profiles is shown in Figure 1. Geographical distribution of respondents. Proportion values are approximate, based on visual estimation from the provided bar chart. Percentages represent the share of the total shown in the chart. Values may not sum exactly to 100% due to rounding. Regarding practice setting, 46.9% of respondents reported working in a mixed healthcare system, 36.6% in the private sector, and 16.5% in the public sector. The majority (64.9%) reported managing fewer than five patients with non‐EoE EGIDs in the previous year. Interdisciplinary work was uncommon, with only 18% stating that they always collaborated with an allergist. Concerning knowledge of the updated nomenclature for non‐EoE EGIDs, 60.5% of participants reported being familiar with it. Detailed characteristics are presented in Table 1. Table 1Sociodemographic and experience‐related characteristics of participants.VariableCategory n %Patients managed in the past year<5 cases20165.05–10 cases7724.911–20 cases196.2>20 cases123.9Collaboration with allergistAlways5517.8Almost always9229.8Sometimes9430.4Almost never3411.0Never3411.0Familiarity with new nomenclatureYes18760.5No12239.5 Note: Percentages are based on the total sample (n = 309). Definitions: “Patients managed in the past year” refers to the number of relevant cases handled by respondents during the previous year. “Collaboration with allergist” indicates the frequency of working with an allergist. “Familiarity with new nomenclature” indicates whether respondents were familiar with the updated terminology.Abbreviation: n, number of respondents.John Wiley & Sons, Ltd. Sociodemographic and experience‐related characteristics of participants. Note: Percentages are based on the total sample (n = 309). Definitions: “Patients managed in the past year” refers to the number of relevant cases handled by respondents during the previous year. “Collaboration with allergist” indicates the frequency of working with an allergist. “Familiarity with new nomenclature” indicates whether respondents were familiar with the updated terminology. Abbreviation: n, number of respondents. Diagnostic practices During endoscopy in patients with suspected non‐EoE EGIDs, 92.2% of respondents reported obtaining biopsies from all gastrointestinal segments, and 80.9% stated that they submitted specimens in separate containers by segment. However, 6.3% performed biopsies only when visible lesions were present. A total of 70.3% reported always performing a panendoscopy when non‐EoE EGID was suspected. Endoscopic monitoring of treatment response was reported as a regular practice by 48.9% of participants, while 26.9% performed it almost always, and 18.8% occasionally. With respect to allergy testing, 37.2% always requested specific immunoglobulin E (IgE) tests to investigate food allergies associated with gastrointestinal symptoms, although a considerable proportion did not routinely use them. Regarding diagnostic biomarkers, 19.4% reported always using peripheral eosinophilia as an adjunctive diagnostic tool, 38.5% used it occasionally, and 10.7% never employed it. Fecal calprotectin measurement was used consistently by 10.0%, whereas 29.5% reported never using it. Skin prick testing for allergens was performed occasionally by 29.1%, while 13.9% reported never using it. The use of imaging studies, such as abdominal ultrasound or computed tomography, was less frequent. Only 12.0% reported always using these modalities, while 34.3% used them occasionally and 21.4% never employed them. Therapeutic practices The management of patients with non‐EoE EGIDs involved a wide range of strategies. It is noteworthy that only 259 participants (65%) responded to this section. Regarding systemic corticosteroids, 17.4% reported always using them (45/259), 34.8% used them occasionally (90/259), and 17.4% never used them (45/259). In terms of treatment duration, 54.3% administered them for between 1 and 3 months (101/186), while 34.4% used them for less than 1 month (64/186). Viscous budesonide was less commonly prescribed. Of the respondents, 16.4% reported always using it (40/244), whereas 32.0% stated they had never used it (78/244). The most common duration of budesonide treatment was 1–3 months (53.6%, 82/153), followed by 3–6 months (24.8%, 38/153). About biological therapies, 88.9% (217/244) reported never having used them, while 11.1% (27/244) indicated prior use. The most frequently reported agents were dupilumab (8.1%, 21/259) and infliximab (2.3%, 6/259). Elimination diets represented a common therapeutic strategy, with 40.2% of respondents (104/259) reporting always using them and 24.7% (64/259) occasionally. Among dietary approaches, 23.2% (60/259) initiated a six‐food elimination diet, while 22.0% (57/259) excluded two foods. Additionally, 20.1% (52/259) reported always employing IgE‐based allergy testing to guide dietary therapy. Other therapeutic practices included the use of proton pump inhibitors (PPIs), reported as a regular strategy by 44.4% (115/259) and as almost always used by 27.8% (72/259). The most frequent treatment duration was 1–3 months (62.8%, 140/223). In contrast, procedural interventions such as endoscopic dilation were rarely employed, with 65.3% (169/259) stating they had never performed it. Similarly, pyloromyotomy for pyloric stenosis was reported as never performed by 74.9% (194/259). For further illustration, see Table 2. Table 2Frequency of use of diagnostic and therapeutic tools in non‐esophageal EGIDs.PracticeAlways/Almost always (n, %)Occasionally (n, %)Never/Almost never (n, %)Panendoscopy216 (69.9%)93 (30.1%)–Biopsy only if visible lesions20 (6.5%)–289 (93.5%)Use of endoscopy for follow‐up151 (48.9%)83 (26.9%)75 (24.3%)Specific IgE114 (36.9%)88 (28.5%)107 (34.6%)Skin prick tests57 (18.4%)65 (21.0%)187 (60.5%)Peripheral eosinophilia60 (19.4%)174 (56.3%)75 (24.3%)Fecal calprotectin31 (10.0%)112 (36.2%)166 (53.7%)Imaging studies (ultrasound, CT scan)37 (12.0%)46 (14.9%)226 (73.1%)Oral systemic corticosteroids45 (17.4%)135 (52.1%)79 (30.5%)Viscous budesonide40 (16.4%)106 (43.4%)98 (40.2%)Biological therapies (any)27 (11.1%)–217 (88.9%)Elimination diets104 (40.1%)137 (52.9%)18 (7.0%)PPIs115 (44.4%)116 (44.8%)28 (10.8%) Note: Values are presented as n (%). Definitions: “Always/Almost always” indicates routine use of the practice; “Occasionally” indicates intermittent use; “Never/Almost never” indicates rare or no use.Abbreviations: CT, computed tomography; EGIDs, eosinophilic gastrointestinal disorders; IgE, immunoglobulin E; PPIs, proton pump inhibitors.John Wiley & Sons, Ltd. Frequency of use of diagnostic and therapeutic tools in non‐esophageal EGIDs. Note: Values are presented as n (%). Definitions: “Always/Almost always” indicates routine use of the practice; “Occasionally” indicates intermittent use; “Never/Almost never” indicates rare or no use. Abbreviations: CT, computed tomography; EGIDs, eosinophilic gastrointestinal disorders; IgE, immunoglobulin E; PPIs, proton pump inhibitors. DISCUSSION EGIDs, excluding EoE, represent a growing challenge in pediatric gastroenterology. The results of this survey provide detailed insights into current diagnostic and management practices for non‐esophageal EGIDs (non‐EoE EGIDs) among pediatric gastroenterologists in Latin America. The variability observed across strategies highlights the need to broaden awareness of recently published international practice guidelines 1 and, potentially, to establish regionally adapted clinical recommendations to optimize patient care. The findings confirm that non‐EoE EGIDs are uncommon in clinical practice, with most respondents reporting fewer than five cases in the past year. 6 , 7 This low prevalence, coupled with limited familiarity with existing international guidelines, 8 suggests restricted individual experience in diagnosis and treatment. Strengthening continuing medical education is therefore crucial to increase diagnostic suspicion, reduce underdiagnosis, and update specialists on appropriate management approaches. 9 , 10 Diagnosis of non‐EoE EGIDs remains largely dependent on histology, with 92.4% of specialists identifying biopsy as the gold standard. However, variability in sampling was observed, with 6.3% performing biopsies only when visible lesions were present. This is concerning, given that EGIDs may occur in the absence of endoscopic abnormalities. 3 Adherence to systematic biopsy protocols across all relevant segments is essential to improve diagnostic accuracy and avoid false negatives. 5 , 7 Studies by Mansoor et al. and Pesek et al. have suggested that capsule endoscopy and novel biomarkers may facilitate earlier detection and reduce reliance on invasive procedures such as conventional upper endoscopy and colonoscopy. 11 , 12 Regarding immunological evaluation, only a minority of specialists reported the use of immune‐based testing in clinical practice: 37.2% performed specific IgE testing, and 18% conducted skin prick testing. Although collaboration with allergists has traditionally been considered valuable for diagnostic assessment, current evidence and the 2024 ESPGHAN/NASPGHAN consensus statement indicate that allergy testing should not guide therapeutic decisions, as these disorders are predominantly non–IgE‐mediated or mixed in nature. 1 Previous studies have shown that immunologic evaluation may provide complementary insights in selected cases but is not necessary for routine management. 13 , 14 Likewise, Kuang et al. reported that patients with hypereosinophilic syndrome may present with clinical features overlapping those of EGIDs, underscoring the importance of thorough differential diagnosis. 15 Accordingly, current guidelines recommend that allergist involvement be optional and reserved for complex phenotypes or patients with substantial concomitant atopic disease. 1 Nevertheless, in certain centers across Latin America, multidisciplinary evaluation including allergist participation remains part of established protocols for patients with food allergies. The use of non‐invasive biomarkers, such as fecal calprotectin, has been proposed as a complementary tool to evaluate intestinal inflammation in EGIDs. Yoo et al. suggested a correlation between elevated calprotectin levels and disease activity. 16 Nonetheless, current guidelines caution that its specificity for EGIDs remains unproven, and further research is required to establish its utility in monitoring these patients. 1 , 6 Management of non‐EoE EGIDs remains heterogeneous, reflecting both the absence of strong consensus and variability in the interpretation of available evidence. While 16.7% of specialists reported routine corticosteroid use, a similar proportion avoided them entirely, suggesting uncertainty about long‐term safety and efficacy. 1 , 6 Budesonide has shown promising benefits in studies such as Siewert et al., 16 though further research is needed to define its precise role. Dietary therapy remains central but demonstrates variable implementation and effectiveness, as highlighted by Furuta et al. and Yamamoto et al. 6 , 14 , 17 The ESPGHAN/NASPGHAN guidelines also emphasize the need for additional controlled studies to validate the efficacy of elimination diets. 1 Antihistamines, leukotriene inhibitors, and mast cell stabilizers have been explored as therapeutic options. While these agents have demonstrated symptom control in selected patient subgroups, overall effectiveness is not yet established. Recent studies suggest potential benefit in patients with a strong allergic component or inadequate response to conventional therapies. 18 , 19 Invasive procedures, such as endoscopic dilation and pyloromyotomy, were rarely reported, consistent with their limited indication for refractory cases. 20 , 21 Biological therapies remain limited, likely reflecting the paucity of robust pediatric data and uncertainty regarding cost‐effectiveness. Dupilumab is currently the only monoclonal antibody approved by the FDA for EGIDs and among the most extensively studied for both esophageal and non‐esophageal EGIDs. 22 , 23 , 24 The heterogeneity observed in non‐EoE EGID management may be explained by several factors. Socioeconomic determinants play a key role, as resource availability, access to specialized medications, and healthcare infrastructure shape therapeutic choices across countries. The absence of regional guidelines further contributes to variability, hindering standardization of care. 10 Limited clinical exposure to these disorders and variability in specialist training may also affect decision‐making. Importantly, non‐EoE EGIDs encompass multiple disease entities under a shared umbrella, differing by organ involvement and depth of infiltration. For instance, in eosinophilic gastritis, topical corticosteroids may be beneficial, whereas in jejunitis they are ineffective. Moreover, when the muscularis mucosae or serosa are affected, topical therapy becomes inadequate, necessitating systemic corticosteroids, dilation in cases of stricture, or biologics targeting the Th2 inflammatory cascade (e.g., dupilumab, Tezepelumab). 2 , 4 The survey results also suggest that implementation of clinical guidelines in low‐ and middle‐income settings may face specific barriers. Limited access to endoscopic and histopathologic resources, variability in healthcare infrastructure, and restricted availability of specialized therapies can hinder guideline adoption. Differences in training opportunities and access to continuing medical education across countries may further limit consistent implementation of international recommendations. Addressing these structural and educational challenges is crucial to ensure that guideline development leads to meaningful improvements in patient care. Standardizing medical curricula across Latin America could improve recognition, diagnosis, and management of non‐EoE EGIDs in children. Regional pediatric gastroenterology, allergy, and pathology societies could define core competencies, including age‐specific clinical features, diagnostic criteria, and basic management principles. Shared training modules, bilingual resources, and inclusion of non‐EoE EGIDs in medical education and pediatric specialty programs may promote earlier diagnosis and more consistent care. Regional research networks and case registries could further support curriculum development and generation of local data. The main limitations of this study include its reliance on self‐reported survey data, which may be subject to recall and selection bias. In addition, uneven geographical representation among participating countries and the absence of objective clinical or histopathologic verification limit the generalizability and external validity of the findings. Despite these limitations, the survey provides a descriptive overview of current practices within the LASPGHAN network and identifies areas where guideline development, professional education, and multicenter research could support more standardized, evidence‐based care for children with non‐EoE EGIDs in Latin America. CONCLUSIONS This survey provides an overview of diagnostic and therapeutic practices for non‐EoE EGIDs among pediatric gastroenterologists in Latin America. Among respondents, substantial variability was observed in endoscopic evaluation, histopathologic criteria, and treatment selection, indicating that clinical approaches differ even within this specialist population. These findings suggest that regionally adapted clinical guidelines—taking into account local epidemiology, healthcare infrastructure, access to diagnostic resources, and structured continuing education—could support more consistent, evidence‐based care and foster collaboration among gastroenterology, allergy, and pathology specialists. The results should be interpreted in light of the study's limitations. Data were obtained from a self‐administered survey using a convenience sample of LASPGHAN members, which may not represent all pediatric gastroenterologists in the region. Response bias and differences in interpretation of survey questions may also influence the findings. Despite these limitations, the survey identifies key areas where guideline development, professional education, and multicenter research could help standardize management and improve outcomes for children with non‐EoE EGIDs in Latin America. CONFLICT OF INTEREST STATEMENT Michelle Higuera Carrillo has received consultant and/or speaker fees from Nestle, Sanofi, Axon Pharma outside the submitted work. Mário Cesar Vieira has received consultant and/or speaker fees from Danone Nutricia, Nestle Nutrition Institute, Sanofi and Aché Laboratories outside the submitted work. Juan Pablo Riveros López has received consultant and/or speaker fees from Danone Nutricia, Abbott, Heel, Axon pharma, Opela, Mead Jhonson, Procter & gamble, Salulac, outside the submitted work. Catalina Ortiz Piedrahita has received consultant and/or speaker fees from Danone Nutricia, Biogaia, outside the submitted work. Ailim Margarita Carias Domínguez has received consultant and/or speaker fees from Danone Nutricia, Abbott, and Nestle outside the submitted work. Sabine Krüger Truppel has received speaker fees from Danone Nutricia and Nestlé Nutrition Institute outside the submitted work and has served as an investigator in phase III clinical trials sponsored by Johnson & Johnson, AbbVie, and AstraZeneca. The remaining authors declare no conflicts of interest. Supporting information supplemental files.